Doctors need better diagnostics and biomarkers for disease severity to improve clinical outcomes and control epidemics

 

 

The diagnostics industry focuses on the “cause” (pathogen) and not on the “effect” (disease severity)

Disease severity matters

 • “Research to provide better diagnostics and biomarkers predicting disease severity are urgently needed” – World Health Organization

 • Measuring and predicting severity is clinically useful for every disease

 

 

FBB Biomed is developing two blood tests

Background: the clinical utility of blood RNA

In January 2019 in Martinsried, Germany, FBB Biomed CEO Dr. Urnovitz laid out his vision of using next generation sequencing, bioinformatics and artificial intelligence to understand the genetic language of the blood – RNA.